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Problematic polypharmacy is a growing challenge. Medication that is intended to improve patients’ 
health and wellbeing is instead becoming part of the problem. The way we practice medicine has 
become one of the drivers for the problems. Dealing with the challenge will need us to think 
differently about how we do clinical care.  
A 2013 Kings Fund report stated that tackling problematic polypharmacy requires us to actively build 
a principle of ‘compromise’ in to the way we use medicines. There are implications for how we 
consult and make decisions with patients, in how we design health practice and systems to support 
that decision making, and in our understanding of the process of research – how we generate the 
knowledge that informs practice.  
This review considers the current state of play in all three areas and identifies some of the work still 
need to do in order to generate the practice-based evidence needed to tackle this most challenging 
problem. 
Finding a way to redesign practice to address problematic polypharmacy could offer a template for 
tackling other related complex issues facing medical practice such as multimorbidity, chronic pain 











The Challenge of Problematic Polypharmacy  
 
Polypharmacy is now a routine medical intervention. Defined as the concomitant use of multiple 
medicines on a long-term basis, it represents an approach to medical care that has expanded 
significantly in scale and scope over the last twenty years [1]. Around one third of people aged 75 
and over take 6 medicines or more a day [2]. The last two decades has seen the number of people 
prescribed 5+ medicines a day increase four-fold [2]. 
Appropriate Polypharmacy offers significant potential benefit to both individual and population 
health [1]. However, the 2013 Kings Fund report also recognises a new challenge – that of 
Problematic Polypharmacy [1].  A person on ten or more medicines a day is over three times more 
likely to be admitted to hospital than someone on 1-3 medicines per day [3]. The risk of adverse 
reactions and medication errors increases with higher prescribing [1]. 40% of people taking 5 or 
more medicines a day report feeling burdened by their use [4]. Many factors contribute to 
problematic polypharmacy, including patient, professional and health system issues. The Kings Fund 
therefore defines problematic polypharmacy with reference to what is experienced by the patient: 
being when the “intended benefit of the medication is not realised” [1]. This definition requires us to 
consider explicitly what we mean by ‘intended benefit’. 
Work to date to address the challenges associated with polypharmacy has centred on the principles 
of medicines optimisation: “ensuring people get the right choice of medicines, at the right time, and 
are engaged in the process by the clinical team” [5]. In practice, this focuses on the safe and 
effective use of medicines to enable the best outcomes [5], involving whole practice teams in safely 
delivering medicines to patients. The intended benefit is optimal medical impact from medication 
with minimal side effects or risk. 
Medicines optimisation programmes have been criticised for a lack of person-centred focus in 
defining ‘best’ practice and outcomes with relation to decisions about medication use [6]. Indeed, 
the 2013 Kings Fund report described that addressing problematic polypharmacy would require 
compromise​ between medical and patient perspectives on the use of medicines [1]. Intended benefit 
may still be biomedical outcomes. For some patients, priorities for care may reflect different 
benefits. 
Achieving compromise in order to meet whole-person needs is the expertise of the medical 
generalist. Generalist practice describes the skills needed to integrate biomedical and biographical 
perspectives of individual illness to generate an individually ​tailored​ interpretation of what is wrong 
and what needs doing [7]. The goal of generalist practice is to support health as a resource for daily 
3 
 
living – a means to an end rather than the end itself [7]. Generalist skills offer a mechanism to deliver 
robust, safe compromise. 
However, the 2019 NHS Long Term Plan recognises a shortage of capacity of generalist skills in the 
hospital setting [8]. In the community/primary care setting, research highlights four barriers to use 
of generalist skills in practice [9] and in particular with reference to decision making around 
prescribing practice  [10]. A 2017 survey of prescribers including GPs, pharmacists and nurse 
prescribers described that tailoring of medicines was inhibited by the 4Ps of Permission, 
Prioritisation, Professional training and Performance management [10]. Professionals described a 
perceived lack of ​permission​ to work beyond guidelines – an approach needed to achieve tailoring 
and compromise. They highlighted a failure to ​prioritise​ this complex task in a multitude of other 
competing priorities in their daily work, meaning they lacked the ‘head space’ to tailor medication 
use. People described both a lack of ​professional training​ in the complex decision making required 
for tailoring, exacerbated by a lack of confidence in using the skills they did have. Finally, they 
challenged ​performance management​ processes which at best ignored , and at worse criticised, this 
area of practice.  
As yet, and for a variety of reasons that I shall return to, we have no evidence-based description of 
an expert-generalist-prescribing intervention. However, we do have a growing body of research 
evidence and professional scholarship that offers us insights in how we could overcome the 
described barriers. This review aims to provide an evidence-informed overview of the state of play 
and proposes next actions for avoiding harm from problematic polypharmacy through strengthening 
expert generalist practice.  
 
Building a generalist response 
 
This review will therefore consider, how can strengthening expert generalist practice support the 
compromise needed to tackle problematic polypharmacy? Underpinning generalist medical practice 
and the delivery of compromise is the principle of person-centred care: that care is guided by the 
needs and preferences of the individual [11], recognising health as a resource for living and not an 
end in itself[12]. Healthcare decisions require an interpretation of illness and need based on 
understanding of the individual in their context, not just their disease status. Delivering 
person-centred care is a complex intellectual task, and certainly not a ‘soft skill’ [13]. 
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To explore this further, I will examine three areas of practice: the consultation (the clinical 
intervention), the practice setting (the context), and scaling and sustaining practice (implications for 
research and scholarship). 
 
Rethinking the consultation 
 
Compromise needs an approach to clinical practice that supports robust and safe construction of 
“contextualised meaning” driving clinical decision making [14,p11]. Generalist practice constructs 
whole-person-centred meaning in context through the integration of knowledge/evidence on both 
the biomedical and biographical aspects of individual illness experience. Decisions are informed by, 
rather than based on, guidelines/evidence, with a clinician exercising the skills and clinical 
judgement of the expert generalist to robustly work beyond guidelines to deliver whole-person 
tailored care [15,16]. Clinicians (health care professionals from across multiple disciplines) using 
generalist skills  create new, tailored knowledge [15] through everyday practice [16]. 
A (still limited) body of scholarship describes how these clinicians work beyond guidelines in 
practice. Gabbay’s account of generating practice-based evidence, and the construction of 
mindlines, describes how GPs actively construct knowledge-in-practice-in-context through the use of 
clinical scholarship [16]. Similarly, Donner-Banzhoff used ethnographic methods to observe GPs in 
practice, and described the “inductive foraging” used by the GPs to construct tailored understanding 
of patients’ illness and needs [13]. Both bodies of research describe the knowledge work 
[17]undertaken (in these cases) by GPs to robustly construct tailored interpretations in context. 
Through professional discussion, we have described these actions as the clinical scholarship [18] of 
professional practice. 
The importance of this interpretive practice – the exercise of clinical judgement – is recognised 
within key systems that currently govern clinical practice. The National Institute for Health and Care 
Excellence (NICE) produces most UK guidelines describing best practice. The Chair of NICE, Professor 
Haslam, has repeatedly described that NICE produces “guidelines not tramlines” [20],  with all NICE 
documents calling for professional judgement. Guidelines are constructed from a review  of best 
evidence (see Box 1). The Evidence Based Medicine (EBM)  movement also supports the use of 
clinical judgement in deciding if and when to apply evidence to an individual patient [21]. Both NICE 
and EBM emphasise the importance of clinical judgement. However, neither  provides a robust 
account describing how we can recognise ‘good’ clinical judgement and in particular, how this 
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‘judgement’  can be distinguished from the ‘clinical opinion’ that appears at the bottom of the EBM 
hierarchy of evidence [22].  
INSERT BOX 1 ABOUT HERE 
As highlighted in my own research [9,10], and within informal discussions with colleagues, clinicians 
feel that they lack the skills and confidence to robustly defend clinical judgement and beyond 
protocol decisions. Professional training (and assessment) focuses on demonstrating what you know, 
rather than how you make use of what you know (for example, to deliver tailored decisions) [23]. 
Professionals feel unable to defend complex decisions, and so they do not make them. This 
undermines the capacity for compromise, and so contributes to problematic polypharmacy. 
 
Responding to the challenge: Tools for generalist prescribing? 
 
A number of tools have been developed to help clinicians “approach the challenge of inappropriate 
polypharmacy” [24]. In the UK, these include the ‘Seven Steps to appropriate polypharmacy’ in the 
Scottish Polypharmacy Guidance [25]; Barnett’s Seven Steps to a patient-centred approach to 
managing polypharmacy in England  [26]; and the All Wales Medicines Strategy Group 
Polypharmacy: guidance for prescribing [27]. All describe the need to undertake a person-centred 
assessment of medicines use in an individual, which considers the goals of care, reasons for taking 
individual medicines, and an understanding of medication adherence or resistance.  
Mangin and colleagues reviewed approaches for reducing inappropriate medication use from across 
the world and generated a set of ten recommendations for reducing inappropriate medication use 
[28]. These include encouraging clinicians to always consider opportunities for deprescribing when 
undertaking medication reviews; correcting the lack of research evidence of outcomes on person, 
rather than disease, focused, medicines use; and highlighting the need for tailored prescribing 
decisions. 
 
What is missing to date from the described models of  prescribing practice is explicit recognition of a 
key barrier to tailored prescribing, namely clinicians’ perception of a lack of permission, skills and 
confidence in ‘beyond protocol’ decision making [9,10]. This gap was recognised by Mangin et al [28] 
in their review which called for a “return to the original concept of EBM”, restoring the role of a 
thoughtful professional “rather than a disease or algorithm technician”. Addressing this gap requires 
attention to the process of knowledge generation (robust interpretation) in practice [15].    Drawing 
6 
 
on the scientific principles of epistemology (the theory of knowledge including how we judge 
between different types of knowledge), I have described a framework (consultation model) that can 
be used to both support and establish the trustworthiness of that aspect of clinical practice  [15,20]. 
 
The SAGE 5 Steps consultation model [20] describes the epistemological principles (5 steps) needed 
to support robust generation of knowledge in practice in context [15] – see Box 2. Clinicians should 
pay attention to, and document their thinking/decision making, with reference to: a clear statement 
of GOALS of care with the default being to support health for daily living; a considered EXPLORATION 
of a full data set; the construction of a TAILORED EXPLANATION; a clear process of professional 
SAFETY NETTING; and follow up of the patient for IMPACT ASSESSMENT. This fifth step recognises 
that a tailored explanation is always an interpretation constructed to support a goal. The quality of 
the interpretation lies in the process of its construction (the first 4 stages) but also its utility – 
whether it offers value to an outcome [15]. 
INSERT BOX 2 ABOUT HERE 
The SAGE 5 Steps model provides a framework that addresses each of the 4P barriers to tailored 
decision making previously described: in recognising the legitimacy of professional interpretive 
practice, and the complexity of the task (and so prioritisation). It provides a framework to support 
the application of skills, and an epistemologically robust framework for critically reviewing and 
defending decision making; as well as performance management/assessment. 
Both the clinical tools described  [25-27] and the SAGE 5 Steps  model [20] can be understood as 
complex interventions supporting professional practice. As such, they  can – and should – be 
subjected to critical evaluation through research in order to understand the impacts on professional 
practice and patient outcomes. The principles behind the SAGE model have been assessed within 
Quality Improvement activity [29]. Both models describe principles of practice that will be 
recognised by and familiar to many professionals:  
“The good physician treats the disease. The great physician treats the person who has the 
disease” (Osler) [cited in 30] 
 However formal research evaluation of either consultation approach has yet to be done. 
 
Addressing barriers: rethinking the organisation of practice 
The polypharmacy models described offer evidence-informed guidance to inform the interaction 
between clinician and patient and so support and change professional practice. But consultations 
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happen in an organisational context. Contextual factors can both support and undermine practice 
[9,10, 31]. Successful implementation of new ways of working requires us to pay attention to the 
context as well as the intervention itself [32]. For generalist expertise to improve the ‘compromise’ 
needed to address problematic polypharmacy, we need to look not just at what clinicians and 
patients are doing, but also to think about the organisation of practice.  
Repeat prescribing supporting long term medication use occurs mainly in the primary care (general 
practice) context. In the UK in 2018, 1.1 billion prescription items were dispensed in the community, 
at a cost of £8.8billion [33]. Improvements to the organisation of prescribing practice has come 
through the development of Medicines Optimisation systems [5]. The principle behind  NHS England 
Medicines Optimisation programme is simple: to “improve outcomes and value” [5]. Measures to 
achieve these goals include the introduction of practice systems that improve outcomes for patients 
by helping them take their medicines correctly, avoid unnecessary medicines and reduce wastage, 
and improve safety [5]. Medicines Optimisation has contributed to significant improvements in 
practice areas such as antibiotic prescribing and reducing the use of medicines that are not clinically 
or cost effective. Utilising the clinical skills of pharmacy teams within primary care settings has been 
a crucial part of this success [5]. 
But Medicines Optimisation approaches, to date, have not fully embraced the challenge of 
implementing ‘compromise’ and in particular the 4P’s to generalist practice that my work has 
described [10]. 
The principles of Medicines Optimisation recognise the importance of a patient-centred approach 
(see Box 3) and so potentially addresses ‘Permission’ as a barrier to person-centred care. However, 
as described practice models do not offer specific guidance on how to ensure that principle #1 
(understanding the patient’s experience) should be used to guide or moderate choices raised by 
principle #2 (evidence based use of medicines). The  approaches to strengthen generalist expertise 
within the SAGE 5 Steps model [20] may help address this challenge. 
INSERT BOX 3 HERE  
 
However further work is also needed to tackle the wider organisational barriers to achieving 
compromise in practice. As discussed, these include how to appropriately prioritise the work needed 
within the wider context of a primary care service, how to build the teams and resources needed to 
support professional practice, and how to appropriately performance manage this complex area of 
work [10].  Again, the research literature offers us insights in to how we might address these wider 
organisational gaps and challenges, including the use of burden measurement tools to identify 
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patients most at risk; building continuity of approach across communities of practice; and the 
revision of performance management tools (see Table 1).  
INSERT TABLE 1 HERE 
As yet, there are no research studies that pull all of these factors together to evaluate a new 
generalist complex intervention to address problematic polypharmacy. We do have a Cochrane 
review evaluating the impact of introducing evidence-based medicines optimisation tools (eg 
STOPP-START, Beers criteria, Medication Appropriateness Index) to address polypharmacy [39]. 
Results demonstrate improved quality and safety governance outcomes (for example, a reduction in 
biomedically defined  inappropriate prescribing) but with uncertain evidence of benefit for ‘clinically 
significant outcomes’ and patient-centred care. Newer studies now seek to evaluate multi-faceted 
(complex) interventions that recognise the range of clinician, patient and context components 
needed to address problematic polypharmacy [40-45].  Each study has a slightly different focus for 
its intervention. It is likely that we will need innovative research methods, for example realist 
synthesis [46], to help us integrate the findings and so draw wider conclusions on redesigning 
prescribing practice. 
 
Implications for research and scholarship 
 
This current body of research will provide us with ‘proof of concept’ statements: evidence of what 
could work to address problems associated with polypharmacy. What comes next is the 
implementation stage – assessing whether the principle works when we seek to deliver it at scale in 
the primary care setting. Implementing complex interventions into everyday practice and at scale 
requires yet another set of knowledge and skills [32,47].  
 
Yet there is a common theme running through each stage discussed here: the theme of knowledge 
work and the robust generation and application of knowledge in, and for, practice [17,18.48,49]. At a 
consultation level, the generalist clinician works to integrate biomedical and biographical 
understanding of illness to generate new knowledge-in-practice of compromise. At a practice level, 
the generalist team works to integrate the multiple elements needed to enable and support this 
complex knowledge work. Now, at the systems level clinicians and academics must work together to 
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integrate the knowledge and insights from their different contexts to co-produce solutions to shared 
problems. 
Evans & Scarborough recognised this process as a new understanding of how research works [49]. 
Their observations of health services research in action revealed two types of practice: bridging and 
blurring. Bridging refers to the (perhaps) more traditional review of scholarship and research: where 
objective knowledge is generated in a controlled setting, with the use of new ‘knowledge 
translation’ tools and workers to deliver this new understanding to the context in which it is to be 
used. They also observed examples of blurring: where academics and applied workers came together 
to co-produce new knowledge-in-context.  The clinical practice of tailored prescribing involves the 
generation of knowledge-in-practice-in-context [16]. Arguably therefore, the generation of robust 
research-evidence describing the mechanisms and impact of such practice requires methodological 
approaches able to deal with this ‘blurring’.  
Evans & Scarborough didn’t seek to judge between the approaches they observed [49]. However, 
they did note that both produce different types of knowledge and so raise questions for us on how 
we judge ‘best’ evidence. Our understanding of best evidence is currently largely driven by the 
epistemological assumptions of the Evidence Based Medicine movement (EBM) [21]. EBM shapes 
both our understanding of ‘best knowledge’ for practice (as discussed), but also best methods for 
producing knowledge (through research). The EBM hierarchy of evidence judges between different 
types of knowledge based on the methodology used to generate it. Yet EBM was originally 
developed within a specialist, biomedical setting and the epistemological assumptions (and so 
hierarchy) reflect the ontological beliefs and knowledge work of that context. However these 
biomedical assumptions about ‘best evidence’ have now been applied more broadly across health 
care setting including into areas which require attention to ‘beyond biomedical’ thinking One 
unintended consequence has been a negative impact on achieving the clinical  compromises 
discussed here [15,28]. 
Glasziou and Chalmers have challenged the current methodology-based definition of best evidence 
on the grounds that it is contributing to research waste: the generation of research that doesn’t 
deliver any impact [50,51]. They propose that research should instead be judged by three 
components: the relevance or appropriateness of the research question, the appropriateness of the 
methodology ​for the question​, and the impact of the research. Their broader vision of research 
quality may offer a framework by which to judge the generation of knowledge from a blurred model 
of research that reverses the current direction of flow of knowledge translation [52]. Instead of 
focusing on the implementation of biomedical research in practice (evidence-based practice), we 
may also use, for example, Living Lab models [54] to capture the ‘daily scholarship’ of clinicians [18] 
10 
 
and patients [6] alike in order to generate  the practice-based evidence [52] needed to develop 
tailored healthcare .  
In conclusion 
Building compromise in to the way we practice medicine, and use medication, will need changes to 
the way we make, use and evaluate clinical decisions – the knowledge work of clinical practice. The 
expertise of generalist practice: built on the robust generation of tailored interpretations of illness 
need; informed, but not driven by, disease-focused evidence offers a way forward. In the UK, the 
need, and urgency, for this shift in direction has been recognised recently  in the publication of the 
Future Doctor Programme [53], and by the work of the WISE GP programme (www.wisegp.co.uk) 
[48]. 
 
Building capacity for clinical compromise will require changes in the way we design and deliver 
healthcare. This review has highlighted the need for a sustained shift in goals of healthcare, 
recognising quality defined by whole-person outcomes (capacity to live daily life); in the training, 
ongoing professional support and performance management of healthcare professionals; and in the 
design of systems supporting learning from practice, including research. Tackling problematic 
polypharmacy will need whole system changes to address barriers to the generation, use and 
assessment of knowledge for practice in real-time and in context. 
We have an opportunity to address a key clinical challenge: how to tailor medical care to the needs 
of the individual patient.  Finding a way to redesign practice to address problematic polypharmacy 
could also offer a template for tackling other related complex issues facing medical practice such as 
multimorbidity, chronic pain and complex mental health. In tackling problematic polypharmacy, we 
may also describe a new model for evidence-informed innovation of practice for the holy grail of 
whole-person-centred healthcare. 
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Box 1: Statement of use within NICE guidelines [24] 
“The recommendations in this guideline represent the views of NICE, arrived at after careful 
consideration of the evidence available. When exercising their judgement, professionals and 
practitioners are expected to take this guidance fully in to account, alongside the needs, 
preferences and values of their patients or the people using their service. It is not mandatory to 
apply the recommendations, and the guidance does not override the responsibility to make 
15 
 
decisions appropriate to the circumstances of the individual , in consultation with them, their 





Box 2: the FIVE STEPS of the SAGE consultation model [19] 
 
The generalist consultation seeks to describe, identify and support health as a resource for daily 
living. This is achieved through focusing on the goals of health care to support daily living. Even 
where medicines are the primary interest of the clinician the consultation focuses on the Goals of 
care, the Gaps in care (outstanding needs) and individuals Grasp (expectations) from the health 
care – including mediation – that they are using. 
 
The specific five steps address: 
 
GOALS of care: the clinician explores a biographical account of living with illness along with the 
goals for, gaps in, and grasp of care. 
 
EXPLORATION: the clinician works the illness experience with reference to the patient’s story, the 
clinician’s contextual knowledge, and biomedical knowledge (including guidelines) 
 
TAILORED EXPANATION: the clinician takes responsibility for (co-)constructing and sharing with 
the patient an explanation of what is happening and why 
 
SAFETY NET: the clinician’s responsibility to identify and address risk 
 
IMPACT: the ultimate test of the interpretation (knowledge constructed) lies in following up with 






Box 3: Medicines Optimisation: four principles of a patient-centred approach [5] 
1. Aim to understand the patients experience 
2. Evidence based choice of medicines 
3. Ensure medicines use is as safe as possible 





Table 1: Potential practice level changes driving improvement in  compromise/expert generalist 
prescribing 
 
BARRIER POTENTIAL SOLUTION 
Prioritisation Identifying patients experiencing problematic polypharmacy  
40% of patients taking 5+ medicines a day feel burdened by their medication 
[4].  This group may benefit from a generalist review and discussion of 
compromise. But 60% of people don’t feel burdened – polypharmacy is 
potentially appropriate, and they may not benefit from additional review. 
Using burden tools such as the Living with Medicines Questionnaire [4] offers 
one way to identify and prioritise patients who may need a different approach. 
Patients have different expectations of medicines [34] which affects the way 
they use, and/or resist, medicines [35]. Prioritising goal setting with patients is 
important. 
Frailty is commonly viewed as one marker of vulnerability to burden and 
problematic polypharmacy – and is a risk factor commonly recorded in primary 
care practice in the UK. However Reeve & Bancroft’s quality improvement work 
suggested that factors predicting need for generalist review are not captured 
solely by biomedical parameters, but relate to issues such as mental health and 
social support [29]. These observations are supported by empirical research 
looking at experiences of living with long term conditions [36]. Prioritisation of 
patients may need to focus on non-biomedical parameters 
Prioritising and Protecting Professional time: 
In 2013, practitioner told us they didn’t have time to tailor clinical decisions in 
trying to fit busy consultations in to short time periods [9]. In 2017, a repeat 
survey now revealed that clinicians didn’t have the ​head space​ [10].  
Practitioners are now regularly engaged in a volume and array of decision 
making. What has been described as the “cognitive load” [37] upon clinicians is 
ever growing. Even with more time, longer consultations, clinicians don’t have 
the capacity to manage the volume of knowledge work expected of them: in 
dealing with complex medical conditions, in contributing to major new 
configuration of services, in managing growing levels of uncertainty. 
A solution focused on longer consultation time with patients, that doesn’t 





Gabbay recognised the importance of teams to support beyond protocol 
decision making and the generation of contextually relevant, collective 
practice-based-evidence (mindlines) from the 
evidence-based-guidelines-for-practice that come from outside of the practice 
context [16]. With General Practice teams evolving, and GP roles change, 
implications for supporting compromise and complex decision making need to 
be thought through. Sharing the data needed for exploration of problems, and 
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the interpretive practice of decision making (see Box 1) requires continuity of 





Performance management drives clinical actions 
[10​http://www.sspc.ac.uk/media/media_486342_en.pdf​]. For example, a 
review of the Scottish Quality & Outcomes framework concluded that 
performance management led to more bureaucratic, less individualised care 
with an increasing biomedical focus [38]. Revitalising generalist 
(whole-person-centred) care will need a review and revision of performance 
management tools. 
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